Johnson & Johnson said today that its pharmaceutical business segment in Ireland will adopt the Johnson & Johnson brand name.
Janssen, J&J's pharmaceutical segment, will become Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.
The company said the change marks the next era for Johnson & Johnson in Ireland.
Johnson & Johnson has had operations in Ireland since 1935 and now has a workforce here of more than 6,000 across ten sites in five counties - Cork, Dublin, Limerick, Galway and Mayo.
Its Irish operations comprise both the Innovative Medicine and MedTech segments and they span research and development, manufacturing, shared services and country commercial businesses.
The company said the changes are part of a global rollout of the new Johnson & Johnson brand that was announced in September 2023. It said the update brand will be applied to all company materials, product packaging, and branding assets over time.
Dana Daneshvari, VP Manufacturing & General Manager, Large Molecule Manufacturing at Johnson & Johnson Innovative Medicine in Ringaskiddy, said that while the name and logo of the pharmaceutical segment of the business is changing, its goal remains the same.
"We innovate with purpose to lead where medicine is going," Mr Daneshvari said.
"As we look to the future, we will continue to build on our legacy of innovation, delivering transformational medicines that improve patient outcomes and make a lasting impact on healthcare in Ireland," he added.
